All In Biotech

Drug Trial Radar · NCT05060822

Phase ll Study of HEC585 in Patients With IPF

A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Jun 30, 2021

Primary completion

Jul 16, 2025

Study completion Dec 11, 2026

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • HEC585Drug

    HEC585 Tablets,once daily

  • PirfenidoneDrug

    Pirfenidone,three times a day

  • PlaceboDrug

    Placebo,once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 24 in %FVC compared with placeboTime frame: 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.